Table 1.
Demographic, disease and treatment variables (n = 1165)
| Variable | Grouping | Frequency | ||
|---|---|---|---|---|
| Male (%) | Female (%) | Total (%) | ||
| Age (years) | 60–64 | 452 (56.43) | 349 (43.58) | 801 (68.76) |
| 65–69 | 102 (53.69) | 88 (46.32) | 190 (16.31) | |
| 70–74 | 60 (59.41) | 41 (40.6) | 101 (8.67) | |
| 75 + | 47 (64.39) | 26 (35.62) | 73 (6.27) | |
| Mean Age (SD) | 64.27 (5.3) | 64.02 (5.12) | 64.16 (5.23) | |
| Diagnosis | Major depressive disorder | 144 (55.82) | 114 (44.19) | 258 (22.15) |
| Anxiety | 108 (51.19) | 103 (48.82) | 211 (18.11) | |
| Mood disorder | 106 (61.63) | 66 (38.38) | 172 (14.76) | |
| Schizophrenia | 66 (56.9) | 50 (43.11) | 116 (9.96) | |
| Dementia | 52 (62.66) | 31 (37.35) | 83 (7.12) | |
| Substance use disorder | 26 (89.66) | 3 (10.35) | 29 (2.49) | |
| Obsessive–compulsive disorder | 12 (60) | 8 (40) | 20 (1.72) | |
| Stress and adjustment disorders | 4 (36.37) | 7 (63.64) | 11 (0.94) | |
| Intellectual disabilities | (0) | 1 (100) | 1 (0.09) | |
| Other disorders | 143 (54.17) | 121 (45.84) | 264 (22.66) | |
| Comorbidities | Diabetes | 101 (58.73) | 71 (41.28) | 172 (14.76) |
| Hypertension | 235 (56.91) | 178 (43.1) | 413 (35.45) | |
| Hypothyroidism | 24 (34.29) | 46 (65.72) | 70 (6.01) | |
| Hyperthyroidism | 3 (37.5) | 5 (62.5) | 8 (0.69) | |
| Cardiovascular diseases | 24 (66.67) | 12 (33.34) | 36 (3.09) | |
| Cerebrovascular disease | 6 (40) | 9 (60) | 15 (1.29) | |
| COPD | 16 (94.12) | 1 (5.89) | 17 (1.46) | |
| Number of drugs | Average N (range) | 3.19 (1–12) | 3.11 (1–16) | 3.16 (1–16) |
| Polypharmacy (5–16) | 140 (58.83) | 98 (41.18) | 238 (20.43) | |
| No polypharmacy (1–4) | 521 (56.21) | 406 (43.8) | 927 (79.57) | |
| 1 | 80 (38.28) | 129 (61.73) | 209 (17.94) | |
| 2 | 149 (47.01) | 168 (53) | 317 (27.21) | |
| 3 | 103 (44.4) | 129 (55.61) | 232 (19.91) | |
| 4 | 74 (43.79) | 95 (56.22) | 169 (14.51) | |
| 5 | 48 (43.25) | 63 (56.76) | 111 (9.53) | |
| 6 | 28 (45.17) | 34 (54.84) | 62 (5.32) | |
| 7 | 11 (44) | 14 (56) | 25 (2.15) | |
| 8 | 7 (35) | 13 (65) | 20 (1.72) | |
| 9 | 2 (25) | 6 (75) | 8 (0.69) | |
| 10 | 1 (25) | 3 (75) | 4 (0.34) | |
| 11 | 0 (0) | 6 (100) | 6 (0.52) | |
| 12 | 0 (0) | 1 (100) | 1 (0.09) | |
| 16 | 1 (100) | 0 (0) | 1 (0.09) | |
| Number of CNS‐active drugs | Average N (range) | 1.86 (1–7) | 1.85 (1–5) | 1.86 (1–7) |
| 1 | 279 (58.13) | 201 (41.88) | 480 (41.2) | |
| 2 | 241 (54.41) | 202 (45.6) | 443 (38.03) | |
| 3 | 91 (55.49) | 73 (44.52) | 164 (14.08) | |
| 4 | 37 (62.72) | 22 (37.29) | 59 (5.06) | |
| 5 | 11 (64.71) | 6 (35.3) | 17 (1.46) | |
| 6 | 1 (100) | 0 (0) | 1 (0.09) | |
| 7 | 1 (100) | 0 (0) | 1 (0.09) | |
| ADR (= 191) | Polypharmacy | 35 (62.5) | 21 (37.5) | 56 (23.5a) |
| No polypharmacy | 68 (50.38) | 67 (49.63) | 135 (14.6b) | |
SD Standard Deviation, CNS Central Nervous System
aproportion of polypharmacy patients having ADR
bproportion of non-polypharmacy patients having ADR